Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera”), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Our lead product is ILUVIEN, now approved for marketing in the U.S. and 15 European countries for the treatment of diabetic macular edema.
Location: United States, Georgia, Alpharetta
Employees: 201-500
Phone: +1 678-990-5740
Founded date: 2003
Investors 4
| Date | Name | Website |
| - | Domain Ass... | domainvc.c... |
| 07.08.2021 | New Enterp... | nea.com |
| - | Hercules C... | htgc.com |
| - | Sofinnova ... | sofinnova.... |
Mentions in press and media 14
| Date | Title | Description |
| 20.08.2024 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, ALIM, INFN on Behalf of Shareholders | NEW YORK, Aug. 20, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders rela... |
| 31.07.2024 | Calliditas Therapeutics: Navigating Shareholder Waters Amidst Corporate Changes | In the world of finance, numbers tell stories. They pulse with the rhythm of market dynamics, reflecting the health of companies and the sentiments of investors. Calliditas Therapeutics AB, a biopharmaceutical company based in Stockholm, re... |
| 26.07.2024 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, CALT on Behalf of Shareholders | NEW YORK, July 26, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders rela... |
| 07.03.2024 | Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results | - |
| 02.06.2022 | Alimera Sciences to Present at the LD Micro Invitational XII Conference | ATLANTA, June 02, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintain... |
| 14.04.2021 | ALIMERA SCIENCES, INC. Alimera Sciences : Receives $20 Million From Ocumension Therapeutics | Alimera grants exclusive license to Ocumension for a $10 million upfront payment and up to $89 million in additional sales-based milestone payments Ocumension makes a $10 million equity investment in Alimera ATLANTA, April 14, 2021 (GLOBE N... |
| 14.04.2021 | Alimera Sciences, Inc. announced that it has received $10 million in funding from Ocumension Therapeutics | Alimera Sciences, Inc. (NasdaqGM:ALIM) announced that it has entered into a share purchase agreement for a private placement of 1,144,945 common shares, par value $0.01 per share, at a purchase price of $8.734044 per share for gross proceed... |
| 18.02.2014 | Alimera raises $37.5M in private placement | Alimera Sciences (NSDQ:ALIM) raised $37.5 million in a recent funding round, planning on using the funds to support general corporate operations. The Atlanta, Ga.-based device maker sold about 6.3 million newly issued shares of common stock... |
| 03.10.2012 | Biotech company developing therapies for macular edema raises $40 million | Solution/Product: The company makes the Iluvien drug delivery system that is implanted at the back of the eye and is designed to release sub-microgram levels of fluocinolone acetonide for up to 36 months to treat chronic diabetic macular ed... |
| 23.04.2010 | Morning Read: Americans more confused than angry over health reform | Why people hate insurance companies: Reuters has a stunning story about Wellpoint, the nation’s largest insurer, and its policy to rescind insurance from women suffering from breast cancer. It’s difficult to do justice to this lengthy, leng... |
Show more